Optic Neuritis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Optic Neuritis – Drugs In Development, 2024 report and make more profitable business decisions.
Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff’s phenomenon, and flashing lights. Risk factors include age and genetic mutations.
The Optic Neuritis drugs in development market research report provide comprehensive information on the therapeutics under development for Optic Neuritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Optic Neuritis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 14 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Optic Neuritis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Optic Neuritis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Optic Neuritis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Cresence ASEnhanX Biopharm Inc
Find Therapeutics Inc
Japan Innovative Therapeutics Inc
Mitochon Pharmaceuticals Inc
Noveome Biotherapeutics Inc
Oculis Holding AG
Parvus Therapeutics Inc
ReNetX Bio
SanBio Co Ltd
The First Affiliated Hospital of Guangxi Medical University
Trethera Corp
University of Pennsylvania
Worphmed Srl
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Optic Neuritis reports